Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

The role of Fas ligand in immune privilege.

Green DR, Ferguson TA.

Nat Rev Mol Cell Biol. 2001 Dec;2(12):917-24. Review.

PMID:
11733771
2.

Immune privilege or inflammation? The paradoxical effects of Fas ligand.

O'Connell J.

Arch Immunol Ther Exp (Warsz). 2000;48(2):73-9. Review.

PMID:
10807046
3.

CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival.

Stuart PM, Griffith TS, Usui N, Pepose J, Yu X, Ferguson TA.

J Clin Invest. 1997 Feb 1;99(3):396-402.

4.

Membrane Fas ligand activates innate immunity and terminates ocular immune privilege.

Gregory MS, Repp AC, Holhbaum AM, Saff RR, Marshak-Rothstein A, Ksander BR.

J Immunol. 2002 Sep 1;169(5):2727-35.

5.

[Fas, fas ligand, immune tolerance, and cancer: implications in cancer of the colon].

Berger A, Piqueras B, Pages F, Tartour E, Cugnenc PH, Fridman WH.

Bull Cancer. 1998 Feb;85(2):129-33. Review. French.

PMID:
9752329
6.

Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack.

Maher S, Toomey D, Condron C, Bouchier-Hayes D.

Immunol Cell Biol. 2002 Apr;80(2):131-7. Review.

7.

A vision of cell death: Fas ligand and immune privilege 10 years later.

Ferguson TA, Griffith TS.

Immunol Rev. 2006 Oct;213:228-38. Review.

PMID:
16972907
8.

A vision of cell death: insights into immune privilege.

Ferguson TA, Griffith TS.

Immunol Rev. 1997 Apr;156:167-84. Review.

PMID:
9176707
9.

Fas ligand-induced apoptosis as a mechanism of immune privilege.

Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA.

Science. 1995 Nov 17;270(5239):1189-92.

PMID:
7502042
10.

CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance.

Griffith TS, Yu X, Herndon JM, Green DR, Ferguson TA.

Immunity. 1996 Jul;5(1):7-16.

11.

The Fas/Fas ligand system and cancer: immune privilege and apoptosis.

Abrahams VM, Kamsteeg M, Mor G.

Mol Biotechnol. 2003 Sep;25(1):19-30. Review.

PMID:
13679631
12.

Fas/Fas ligand on the road: an apoptotic pathway common to AIDS, autoimmunity, lymphoproliferation and transplantation.

Famularo G, Nucera E, Marcellini S, De Simone C.

Med Hypotheses. 1999 Jul;53(1):50-62.

PMID:
10499826
13.

Induction of tolerance using Fas ligand: a double-edged immunomodulator.

Askenasy N, Yolcu ES, Yaniv I, Shirwan H.

Blood. 2005 Feb 15;105(4):1396-404. Epub 2004 Oct 14. Review.

14.

The role of FasL-induced apoptosis in immune privilege.

Griffith TS, Ferguson TA.

Immunol Today. 1997 May;18(5):240-4. Review. No abstract available. Erratum in: Imunol Today 1997 Jul;18(7):361.

PMID:
9153956
15.

Immune privilege or inflammation? Insights into the Fas ligand enigma.

O'Connell J, Houston A, Bennett MW, O'Sullivan GC, Shanahan F.

Nat Med. 2001 Mar;7(3):271-4.

PMID:
11231613
16.

Spontaneous tolerance: experience with the rat liver transplant model.

Dresske B, Lin X, Huang DS, Zhou X, Fändrich F.

Hum Immunol. 2002 Oct;63(10):853-61.

PMID:
12368037
17.

Specific deletion of autoreactive T cells by adenovirus-transfected, Fas ligand-producing antigen-presenting cells.

Zhan HG, Mountz JD, Fleck M, Zhou T, Hsu HC.

Immunol Res. 2002;26(1-3):235-46. Review.

PMID:
12403361
18.

The Fas counterattack: cancer as a site of immune privilege.

O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F.

Immunol Today. 1999 Jan;20(1):46-52. Review. No abstract available.

PMID:
10081230
19.

Cell death and immune privilege.

Ferguson TA, Green DR, Griffith TS.

Int Rev Immunol. 2002 Mar-Jun;21(2-3):153-72. Review.

PMID:
12424841
20.

Termination of antigen-specific immunity by CD95 ligand (Fas ligand) and IL-10.

Barreiro R, Luker G, Herndon J, Ferguson TA.

J Immunol. 2004 Aug 1;173(3):1519-25.

Items per page

Supplemental Content

Write to the Help Desk